Tumour suppressor TRIM33 targets nuclear β-catenin degradation
Jianfei Xue(The University of Texas MD Anderson Cancer Center), Suyun Huang(The University of Texas MD Anderson Cancer Center), Yaohui Chen(Huazhong Agricultural University), Kenneth Aldape(National Institutes of Health), Sadhan Majumder(The University of Texas MD Anderson Cancer Center), Zhimin Lu(Shandong Sport University), Zhongyong Wang(Korea University), Sicong Zhang(Harbin University of Commerce), Yamei Wu(Sichuan Agricultural University), Aidong Zhou(Zhujiang Hospital), Kangyu Lin(The University of Texas MD Anderson Cancer Center)
Cited by 155
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Lipid metabolism and cancer
|The Journal of Experimental Medicine|2020|981
Challenges to curing primary brain tumours
|Nature Reviews Clinical Oncology|2019|965